Introduction
Aztreonam is the first of a new class of P lactam antibiotics, the monobactams, which have a novel monocyclic structure. The compound has a narrow range of activity directed against aerobic Gram negative bacteria, is stable to most of the common Gram negative P lactamases and, unlike many other P lactam drugs, fails to induce the production of chromosomally mediated enzymes. ' The drug is not absorbed after oral administration and needs to be given parenterally. After a single 1 g intramuscular dose the mean serum concentration at one hour is 40 mg/i and the mean urine concentration at two hours is 1200 mg/l: the elimination half life of the drug is 1.3-2 hours. 2 The minimum inhibitory concentration of aztreonam for Neisseria gonorrhoeae, including P lactamase producing strains, has been reported as 0.1-0-2 mg/1,3 and the successful treatment of gonorrhoea with this drug has been reported. 4 
